# chronic pruritus of unknown origin FDA approvals and PDUFA dates

Canonical: https://sec-api.dev/indications/chronic-pruritus-of-unknown-origin

> 7 upcoming FDA catalysts in chronic pruritus of unknown origin: ATTO-1310 (ATTO) on 1H 2027 (trial start); ATTO-1310 (ATTO) on Aug to Nov 2028 (topline data readout); ATTO-1310 (ATTO) on August 2028 (primary completion); Rhapsido® (remibrutinib, NVS) on Feb to May 2029 (topline data readout); and 3 more.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: half-year only, quarter only, month only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Verified answer

### What are the upcoming FDA decisions for chronic pruritus of unknown origin?

7 upcoming FDA catalysts in chronic pruritus of unknown origin: ATTO-1310 (ATTO) on 1H 2027 (trial start); ATTO-1310 (ATTO) on Aug to Nov 2028 (topline data readout); ATTO-1310 (ATTO) on August 2028 (primary completion); Rhapsido® (remibrutinib, NVS) on Feb to May 2029 (topline data readout); and 3 more. Press release filed with the SEC (EX-99): "Initiation of global Phase 2 trials of ATTO-1310 in patients with chronic pruritus of unknown origin (CPUO) and high-itch AD expected in 1H 2027" [Calendar and source filings](https://sec-api.dev/indications/chronic-pruritus-of-unknown-origin)

Source: Press release filed with the SEC (EX-99), accession 0001193125-26-453592, https://www.sec.gov/Archives/edgar/data/2058707/000119312526453592/atto-ex99_1.htm (retrieved 2026-11-12). Last confirmed 2026-11-09. Cite: https://sec-api.dev/indications/chronic-pruritus-of-unknown-origin#answer

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| 1H 2027 | [ATTO-1310 trial start](https://sec-api.dev/pdufa/atto-1310) | ATTO | chronic pruritus of unknown origin | scheduled | "Initiation of global Phase 2 trials of ATTO-1310 in patients with chronic pruritus of unknown origin (CPUO) and high-itch AD expected in 1H 2027" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/2058707/000119312526453592/atto-ex99_1.htm)) |
| Aug to Nov 2028 | [ATTO-1310 topline data readout](https://sec-api.dev/pdufa/atto-1310) | ATTO | Chronic Pruritus of Unknown Origin | scheduled | "NCT07833306 (Efficacy and Safety of ATTO-1310 in the Treatment of Participants With Chronic Pruritus of Unknown Origin): Overall Status NOT_YET_RECRUITING; Phase PHASE2; Primary Completion 2028-08-30 (ESTIMATED); Lead Sponsor Attovia Therapeutics Inc." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07833306)) |
| August 2028 | [ATTO-1310 primary completion](https://sec-api.dev/pdufa/atto-1310) | ATTO | Chronic Pruritus of Unknown Origin | scheduled | "NCT07833306 (Efficacy and Safety of ATTO-1310 in the Treatment of Participants With Chronic Pruritus of Unknown Origin): Overall Status NOT_YET_RECRUITING; Phase PHASE2; Primary Completion 2028-08-30 (ESTIMATED); Lead Sponsor Attovia Therapeutics Inc." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07833306)) |
| Feb to May 2029 | [Rhapsido® (remibrutinib) topline data readout](https://sec-api.dev/pdufa/remibrutinib) | NVS | Chronic Pruritus of Unknown Origin | scheduled | "NCT07811869 (A Study to Evaluate Efficacy, Safety, and Tolerability of Remibrutinib in Adult Participants With Severe Chronic Pruritus of Unknown Origin (CPUO)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2029-02-26 (ESTIMATED); Lead Sponsor Novartis Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07811869)) |
| February 2029 | [Rhapsido® (remibrutinib) primary completion](https://sec-api.dev/pdufa/remibrutinib) | NVS | Chronic Pruritus of Unknown Origin | scheduled | "NCT07811869 (A Study to Evaluate Efficacy, Safety, and Tolerability of Remibrutinib in Adult Participants With Severe Chronic Pruritus of Unknown Origin (CPUO)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2029-02-26 (ESTIMATED); Lead Sponsor Novartis Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07811869)) |
| Dec 2029 to Mar 2030 | [Rhapsido® (remibrutinib) topline data readout](https://sec-api.dev/pdufa/remibrutinib) | NVS | Chronic Pruritus of Unknown Origin | scheduled | "NCT07700056 (A Study to Evaluate Efficacy, Safety and Tolerability of Remibrutinib in Adult Participants With Severe Chronic Pruritus of Unknown Origin (CPUO)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2029-12-19 (ESTIMATED); Lead Sponsor Novartis Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07700056)) |
| December 2029 | [Rhapsido® (remibrutinib) primary completion](https://sec-api.dev/pdufa/remibrutinib) | NVS | Chronic Pruritus of Unknown Origin | scheduled | "NCT07700056 (A Study to Evaluate Efficacy, Safety and Tolerability of Remibrutinib in Adult Participants With Severe Chronic Pruritus of Unknown Origin (CPUO)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2029-12-19 (ESTIMATED); Lead Sponsor Novartis Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07700056)) |

## Drugs

- [ATTO-1310](https://sec-api.dev/pdufa/atto-1310) (ATTO)
- [Rhapsido® (remibrutinib)](https://sec-api.dev/pdufa/remibrutinib) (NVS)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/indications/chronic-pruritus-of-unknown-origin.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "chronic pruritus of unknown origin FDA approvals and PDUFA dates." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/indications/chronic-pruritus-of-unknown-origin

```bibtex
@misc{secapidev_indications_chronic_pruritus_of_unknown_origin_20261116,
  title        = {chronic pruritus of unknown origin FDA approvals and PDUFA dates},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/indications/chronic-pruritus-of-unknown-origin}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_indications_chronic_pruritus_of_unknown_origin_20261116","title":"chronic pruritus of unknown origin FDA approvals and PDUFA dates","publisher":"sec-api.dev","URL":"https://sec-api.dev/indications/chronic-pruritus-of-unknown-origin","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
